linjc16/ctgov huggingface dataset:
Measurement of Cardiac Output and Blood Volumes

Study Overview
=================
Brief Summary
-----------------
Cardiac Output (amount of blood pumped by the heart in one minute) will be measured using the new COstatus(R) system and these values will be compared with cardiac output values measured by other methods such as thermodilution. Blood volumes measured by the COstatus(R) system will also be recorded.

Official Title
-----------------
Measurement of Cardiac Output and Blood Volumes

Conditions
-----------------
Cardiac Output

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients (older than 18 years of age) Should have both arterial and central venous catheters already in place Exclusion Criteria: Patients who do not have either the arterial or central venous catheters.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Compare cardiac output measured by COstatus(R) with other methods such as PA Thermodilution |  | 5-8 minutes minimum | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measure blood volumes |  | 5-8 minutes minimum | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COstatus(R), Ultrasound Dilution, Cardiac Output, Blood Volumes, Comparison of COstatus(R) cardiac output with other methods
SPHERE Hypertension Baseline Data Study

Study Overview
=================
Brief Summary
-----------------
We are collecting baseline data on patients who have high blood pressure readings (160/100 or higher) at a 9-1-1 response by an EMT.

Detailed Description
-----------------
We are collecting baseline data on patients who have high blood pressure readings (160/100 or higher) at a 9-1-1 response by an EMT. We want to understand what these patients currently remember occurring during the 9-1-1 response around their high blood pressure measure; if the patients seek a second reading; if the patients seek follow-up care as a result of the high blood pressure measure. We are also interested if patients trust EMTs as a provider of preventive health care. This baseline data will also allow us to more accurately measure the success of a future intervention study aimed at motivating subjects to receive a follow-up hypertension assessment from a physician after receiving a high blood pressure reading from an EMT.

Official Title
-----------------
SPHERE Hypertension Baseline Data Study

Conditions
-----------------
Hypertension

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Systolic blood pressure greater than or equal to 160 and/or diastolic blood pressure greater than or equal to 100 Patient is at least 18 years old Patient was not transported by paramedics Patient was not admitted to a hospital Patient is not a nursing home/adult family home resident Patient's phone number is listed in the MIRF database Exclusion Criteria: not meeting inclusion criteria

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Evaluating Deep Breathing in Health Participants Using a Device Called Impulse Oscillometry

Study Overview
=================
Brief Summary
-----------------
This study will determine if resistance of the airway to airflow and pressure, measured by Impulse Oscillometry, is impacted by a deep breathe maneuver in a small cohort of healthy human subjects.

Official Title
-----------------
Impulse Oscillometry and the Bronchoprotective Effects of Deep Inspiration

Conditions
-----------------
Breathing, Mouth, Lung Function Decreased

Intervention / Treatment
-----------------
* Device: Impulse Oscillometer


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Vaccinated against COVID-19 Ability to provide informed consent Willingness to perform breathing test Willingness to provide basic demographic data Must be able to speak and understand English Exclusion Criteria: Unable to or unwilling to provide consent, perform test, or provide basic demographic data

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| All participants<br> | Device: Impulse Oscillometer<br>* The tremoFlo C-100 Airwave Oscillometry System is intended to measure respiratory system impedance using the Forced Oscillation Technique (FOT).<br>* Other names: THORASYS tremoFlo C-100 Airwave Oscillometry System;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean respiratory system impedance | The oscillometer will collect an airway impedance measurement which is made up of multiple variables. | pre deep inspiration, approximately day 1 | 
| Mean respiratory system resistance | The oscillometer will collect an airway impedance measurement which is made up of multiple variables. | post deep inspiration, approximately day 1 | 
| Mean change in respiratory system resistance | The oscillometer will collect an airway impedance measurement which is made up of multiple variables. | post and pre deep inspiration, approximately day 1 |
Individual Patient Expanded Access IND for Selexipag (Uptravi) in Participants With Non-healing Wound, Buerger's Disease

Study Overview
=================
Brief Summary
-----------------
The purpose of this expanded access program (EAP) is to provide Selexipag (Uptravi) for the treatment of participant with non-healing wound, buerger's disease.

Official Title
-----------------
Individual Patient Expanded Access IND for Selexipag (Uptravi) in Participants With Non-healing Wound, Buerger's Disease

Conditions
-----------------
Non-healing Wound, Thromboangiitis Obliterans

Intervention / Treatment
-----------------
* Drug: Selexipag


Participation Criteria
=================

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Selexipag|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
ETI During Intubation

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to compared effectiveness of intubation using ETView VivaSight SL and standard tracheal tube during resuscitation performed by a novice-physicians.

Official Title
-----------------
Can the ETView VivaSight SL Rival the Macintosh Laryngoscopy With Conventional Tube During Adult Resuscitation by Novice Physicians: a Randomized Crossover Simulation Study.

Conditions
-----------------
Intubation, Cardiac Arrest

Intervention / Treatment
-----------------
* Device: Standard tracheal tube
* Device: ETView VivaSight SL


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: give voluntary consent to participate in the study maximum 1 year of work experience in medicine maximum 10 clinical intubations Exclusion Criteria: not meet the above criteria wrist or low back diseases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: ETI with chest compressions<br>endotracheal intubation (ETI) during child mannikin resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.). | Device: Standard tracheal tube<br>* Intubation using Macintosh laryngoscope and standard tracheal tube<br>Device: ETView VivaSight SL<br>* Intubation using ETView VivaSight SL<br>|
| Experimental: ETI without chest compressions<br>Endotracheal intubation of child mannikin during resuscitation without chest compressions. | Device: Standard tracheal tube<br>* Intubation using Macintosh laryngoscope and standard tracheal tube<br>Device: ETView VivaSight SL<br>* Intubation using ETView VivaSight SL<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to intubation | time from insertion of the blade to the first manual ventilation of the manikin´s lungs. If time of intubation is over than 60 seconds, attempt was recognized as failure. | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Success of intubation | effectiveness of the first, second and third intubation attempts and overall effectiveness of intubation by participants using four intubation devices. If the examinee failed at all attempts, the case was excluded from the time calculations. | 1 day | 
| Cormack-Lehan scale | self reported Cormack-Lehan scale during intubation | 1 day |
Safety and Efficacy of Oral Bovine Lactoferrin

Study Overview
=================
Brief Summary
-----------------
Oral lactoferrin versus Placebo will be given to preterm neonates

Detailed Description
-----------------
200 patient were included in the study , one hundred received oral placebo in the form of 2 ml saline , the other 100 preterm neonates received oral lactoferrin with monitoring of C-reactive protein , different cultures, complete blood count on day 7 and after one month.

Official Title
-----------------
Effectivness and Safety of Oral Bovine Lactoferrin in Neonatal Sepsis and Necrotizing Enterocolitis and Its Effect on Anaemia of Prematurity

Conditions
-----------------
Neonatal SEPSIS

Intervention / Treatment
-----------------
* Drug: Lactoferrin
* Drug: Placebos


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All neonates born at Cairo university hospital NICU Exclusion Criteria: Neonatal deaths before 3 days postnatal . Neonates with underlying gastrointestinal problems that prevent oral intake. Neonates with major congenital anomalies . Neonates with severe hypoxic ischemic encephaloapathy . Neonates whose parents refuse to participate.

Ages Eligible for Study
-----------------
Minimum Age: 1 Day
Maximum Age: 7 Days

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: placebo group 100 patient will receive 2 ml saline for one month in comparison with oral lactoferrin for the same period to another 100 patient
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: placebo<br>saline is given orally in dose of 2 ml per day for one month | Drug: Placebos<br>* placebp is given in 2 ml saline<br>* Other names: saline;|
| Active Comparator: lacoferrin<br>Pravotin is given orally 100 mg per sachet dissolved in 5 ml water given for one month | Drug: Lactoferrin<br>* lactoferrin is given orally in comparsion to placebp<br>* Other names: Pravotin sachets;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in mortality rate of neonatal sepsis in preterm neonate | Neonates will be assessed by C-reactive protein and different cultures to identify Neonatal sepsis | one year | 
| Number of Preterm Neonates who will have long term Complication after one month of regular use of Lactoferrin | Neonates will be assessed for long term complication as necrotizing enterocolitis , retinoapathy of prematurity and bronchopulmonary dysplasia | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
lactoferrin
Effects of Age on Amino Acid Delivery to Tendon

Study Overview
=================
Brief Summary
-----------------
Dietary amino acid supplementation may provide an effective means to promote tendon injury recovery and enhance collagen synthesis. While most published research has been completed in animal models, research with young adults has shown that a leucine-rich whey isolate consumed during a chronic resistance training (RT) intervention resulted in greater gains ( 60%) in tendon CSA when compared to placebo. Leucine-rich diets have also improved tendon collagen content in rodents. Further, in our preliminary work utilizing microdialysis, we demonstrate that oral consumption of a leucine-rich amino acid beverage increased delivery of amino acids to tendons in young adults (21-30 years). However, whether aging alters the delivery of amino acids to tendons after oral consumption has not be investigated. In order to optimize amino acid dosing for chronic interventional studies, we wish to determine if aging influences amino acid concentration in the peritendinous (space around the tendon) space after oral consumption.

Official Title
-----------------
Effects of Age on Amino Acid Delivery to Tendon

Conditions
-----------------
Aging

Intervention / Treatment
-----------------
* Dietary Supplement: Amino Acids


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Exclusion Criteria: body mass index >35 kg•m-2, those on medications known to affect protein or collagen metabolism, e.g. acetaminophen, ibuprofen, or prescription cyclooxygenase inhibitors, previous history of tendinopathy, or diabetes.

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Non-Randomized
Intervention Model: Factorial Assignment
Interventional Model Description: Young (21-30 years old) and older (60-75 years) adults will each receive an oral bolus of 10 g of essential amino acids.
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Young<br>Young adults will be given a 10 g oral bolus of amino acids. | Dietary Supplement: Amino Acids<br>* 10 g bolus of essential amino acids<br>|
| Experimental: Older Adults<br>Older adults will be given a 10 g oral bolus of amino acids. | Dietary Supplement: Amino Acids<br>* 10 g bolus of essential amino acids<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Achilles Peritendinous Amino Acid Levels in young and older adults | Concentrations of amino acids will be measured from around the Achilles tendon | 0-6 hours post consumption | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
amino acid, tendon, aging
Continuation Treatment Protocol for Patients Who Participated in the Adagio TVP 1012/501 Clinical Trial

Study Overview
=================
Brief Summary
-----------------
the purpose of the study is to extend the use of Rasagelin Mesylate 1mg per day by subjects who participated in the Adagio TVP 1012/501 according to form 4a for additional three years.

Official Title
-----------------
Continue Providing Care for Patient Who Participated in the Adagio TVP 1012/501 Clinical Trial

Conditions
-----------------
Parkinson Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: subjects who are willing to contiue this treatment. subjects who took part in the TVP 1012/501 clinical trail. Exclusion Criteria: subjects who didn't take part in the TVP 1012/501 clinical trail.

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Effect of l S Exercises on Balance and Spatiotemporal Gait Parameters in P M Women

Study Overview
=================
Brief Summary
-----------------
Menopause is a natural process in women's life with hormonal fluctuations that cause physical and emotional symptoms such as(Hot flashes, insomnia, physical in activity, unstable mood, difficulties in memory and concentration, anxiety, stress, irritability, unstable body mass, sexual dysfunction, feelings of sadness, infertility, and depression). Balance disturbances are common in the community as a whole and increase in frequency with age. The risk of falling increases from age 45 in women and peaks in the 55-59-year age group. Around the time of the menopause, estrogen production decreases dramatically and bone loss accelerates, which predisposes for fractures if a fall occurs.

Official Title
-----------------
Effect of Lumbar Stabilization Exercises on Balance and Spatiotemporal Gait Parameters in Postmenopausal Women

Conditions
-----------------
Postmenopausal

Intervention / Treatment
-----------------
* Other: lumbar stabilization exercises


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Post-menopausal women: Their age will be ranged between 45-59 years old, with low back pain. Exclusion Criteria: Infection disease or fever. Foot ulcers. Foot infection or undergoing foot surgery. Recent fracture in foot and toes with unhealed wounds. Thrombotic disease of lower extremities. Deep proprioception loss. Peripheral neuropathy. Gout or advanced arthritis affecting the foot and toes.

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 59 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Group (A)<br>Group (A): will receive lumbar stabilization exercises | Other: lumbar stabilization exercises<br>* selected exercises will taught to participant and practiced 3 times per week for 6 weeks<br>|
| No Intervention: Group (B)<br>Group (B): will be control group. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Step length | the distance between the point of initial contact of one foot and the point of initial contact of the opposite foot measured by cm | about 6 weeks. | 
| step symmetry | right to left time distribution measured by second | about 6 weeks. | 
| walking speed | the ratio of distance to the time in which the distance was covered by the subject measured by m/s | about 6 weeks. |
Treatment of Systemic Lupus Erythematosus With Pooled Allogenic Mesenchymal Stem Cells

Study Overview
=================
Brief Summary
-----------------
Treatment of systemic lupus erythematosus with pooled allogenic mesenchymal stem cells

Official Title
-----------------
Treatment of Systemic Lupus Erythematosus With Pooled Allogenic Olfactory Mucosa Derived Mesenchymal Stem Cells

Conditions
-----------------
Systemic Lupus Erythematosus

Intervention / Treatment
-----------------
* Biological: Pooled mesenchymal stem cell
* Other: Standard treatment according to the Clinical protocols


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: SLE diagnosis (4 of 11 criteria by ACR); positive dsDNA; SELENA-SLEDAI index ≥6; active lupus nephritis; patient can read, understand and follow the procedures. Exclusion Criteria: need for dialysis; planned renal transplantation; any medical condition which can be associated with the high risk for the patient; pregnancy/lactation; chronic infections, including hepatitis B/C, tuberculosis, HIV; any malignant tumor in the last 5 years.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: SLE patients MSC treatment<br>Patients with SLE, who receive pooled mesenchymal stem cells in addition to the standard treatment according to the Clinical protocols | Biological: Pooled mesenchymal stem cell<br>* Pooled allogenic mesenchymal stem cell derived from olfactory mucosa<br>Other: Standard treatment according to the Clinical protocols<br>* Standard SLE treatment according to the Clinical protocols approved by the Ministry of healthcare of Republic of Belarus<br>|
| Active Comparator: SLE patients standard treatment<br>Patients with SLE, who receive standard treatment according to the Clinical protocols | Other: Standard treatment according to the Clinical protocols<br>* Standard SLE treatment according to the Clinical protocols approved by the Ministry of healthcare of Republic of Belarus<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy evaluation | Efficacy evaluation (SELENA-SLEDAI) | 6 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety eveluation | Absence of adverse reactions | 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Systemic Lupus Erythematosus, mesenchymal stem cells